Twist Bioscience (TWST) Delivers Fiscal 2026 Growth, Margin Lift, and a $550–$560M Revenue Forecast for 2027
In a world where investors obsess over EPS rhythms and earnings surprises, Twist Bioscience (TWST) rolled out a fiscal 2026 story that leans into scale, margin discipline, and a confident revenue forecast for 2027. The company reported full-year revenue of $459.4 million, up 22% from $376.6 million in the prior year, and posted a 4QFY26 revenue print of $126.6 million, roughly 28% higher than the year-ago quarter. The ticker TWST faces questions not about clever pivots, but about whether this growth can translate into durable profitability as it scales capacity and automation.
Highlights: Revenue, Segments, and Margins
Two core segments powered the year: DNA Synthesis and Protein Solutions (DSPS) and NGS Applications (NGS). DSPS revenue rose 31.7% to $221.9 million in fiscal 2026, while NGS revenue grew 14.1% to $237.5 million. Together they drove total revenue of $459.4 million, a clear signal of demand across Twist’s product portfolio. On the cost side, total cost of revenues came in at $218.6 million for fiscal 2026, leaving a gross margin of 52.4%—an expansion of 1.7 percentage points from 50.7% in fiscal 2025. In other words, the company widened its gross margin despite higher revenue run rate, a sign of improving mix and scale effects rather than just price of admission.
Capital Allocation and Non-GAAP Footnotes
The release foregrounds non-GAAP information and an associated reconciliation table, a reminder that investors often chase adjusted EBITDA and other metrics when GAAP earnings per share (EPS) get complicated by stock-based compensation, amortization, and other one-off items. Twist emphasized its focus on capacity expansion, automation, and new product development—investments that can support higher run rate and liquidity as the business moves through its next growth phase. The press statement does not provide a GAAP EPS figure in the release, but market participants will be aligning to EPS expectations via the EPS consensus and watching for any earnings surprise relative to those expectations.
Guidance: Revenue Forecast for Fiscal 2027 and Q1 2027
Guidance matters more than a quarterly flourish, and Twist delivered a clear revenue forecast for fiscal 2027: $550 million to $560 million, implying ~21% year-over-year growth at the midpoint. The company also offered a first-quarter FY2027 revenue outlook of $130 million to $132 million, setting a midpoint that suggests roughly 26% growth versus the prior year’s first quarter. For readers and analysts, this is a signal that management sees continued momentum across both DSPS and NGS, with automation and capacity investments aimed at sustaining a higher mix of higher-margin production lines.
Management Commentary and Strategic Context
Emily M. Leproust, Ph.D., Twist’s CEO and co-founder, framed fiscal 2026 as a demonstration of the company’s ability to grow top-line revenue, expand gross margin, and generate positive adjusted EBITDA while continuing to strengthen the balance sheet. The theme—scaling with a focus on efficiency and product diversification—reads as a blueprint for the next phase of growth: invest in capacity, automate processes, and broaden the product set to meet demand in discovery, diagnostics, and therapeutics. As Leproust put it, the company is building the infrastructure for where the industry is going, supporting the idea that Twist aims to be indispensable to the next generation of molecular design and manufacturing at scale.
What This Might Portend for TWST and Its Peers
Twist’s fiscal 2026 results portray a company that has moved beyond startup jitters to a more disciplined growth narrative. The 52.4% gross margin, paired with double-digit top-line growth across both DSPS and NGS segments, suggests the business is leveraging scale to improve profitability—not merely growing headcount to chase revenue. If this trajectory holds, the stock could trade more on efficiency of scale and how much of the margin uplift is durable versus a near-term mix shift.
For sector peers, Twist’s narrative might catalyze a broader reassessment of how DNA synthesis, protein solutions, and NGS offerings can be bundled as complementary growth engines. Investors will look for a sustainable path to higher gross margins and positive EBITDA, which in turn elevates the quality of earnings for a space that’s historically capital-intensive and cycle-sensitive. The emphasis on capacity and automation also underscores a trend: firms that invest in scalable, automated platforms may weather demand volatility better than those relying on labor-intensive or commodity-driven processes.
Risks and Considerations
Non-GAAP metrics, reconciliation tables, and the absence of explicit GAAP EPS in the release mean investors should triangulate Twist’s earnings quality through cash flow, EBITDA trends, and the durability of gross margin gains. As always with high-growth tools players, questions linger about the pace of capital expenditure, manufacturing lead times, and competition in both the DSPS and NGS arenas. A robust revenue forecast helps, but the real test will be whether the company can translate top-line strength into sustained, divisible profit margins as it scales.
Bottom Line: A Growth Narrative with Margin Wind
Twist’s fiscal 2026 results suggest a company successfully balancing growth with margin expansion, backed by a forward-looking revenue forecast for 2027 that sits at a healthy double-digit growth rate at the midpoint. The stock's immediate reaction will hinge on how well investors interpret the durability of that margin lift and the realism of the 2027 guidance. For those tracking TWST, the monitor signal is simple: revenue forecast elevated, gross margin stable to rising, and a strategic emphasis on automation and capacity that could set a precedent for peers in the biotech tools space. The next chapters will reveal whether this is enough to turn momentum into sustained earnings power—an outcome that would echo across the sector and perhaps reset the pace of anticipated EPS discourse for the whole field.
Note: This article references TWST's fiscal 2026 results as reported in the release dated November 12, 2026, including full-year and Q4 specifics as well as 2027 revenue guidance. EPS commentary reflects analyst focus on non-GAAP information and reconciling metrics, rather than a stated GAAP EPS figure in the release.